ArticleImmunobiology2007
The SARS coronavirus spike glycoprotein is selectively recognized by lung surfactant protein D and activates macrophages.
Article in Immunobiology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 1 synthesis or guideline pooled it, 145 citations in OpenAlex.
- [Pulmonary innate immune response in Sars-cov-2 infection]Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) · 2022Pooled it
- Roles of sex and SP-A genetic variants in modulating multiorgan injuries post viral infection.Frontiers in immunology · 2026Article
- Human surfactant protein A inhibits SARS-CoV-2 infectivity and alleviates lung injury in a mouse infection model.Frontiers in immunology · 2024Article
- Surfactant replacement therapy as promising treatment for COVID-19: an updated narrative review.Bioscience reports · 2023Review
- In vivo inhibition of nuclear ACE2 translocation protects against SARS-CoV-2 replication and lung damage through epigenetic imprinting.Nature communications · 2023Article
- Risk Factors for Respiratory Viral Infections: A Spotlight on Climate Change and Air Pollution.Journal of asthma and allergy · 2023Review
- Elevated plasma levels of epithelial and endothelial cell markers in COVID-19 survivors with reduced lung diffusing capacity six months after hospital discharge.Respiratory research · 2022Observational
- Pulmonary surfactant as a versatile biomaterial to fight COVID-19.Journal of controlled release : official journal of the Controlled Release Society · 2022Review
- Review
- Insights Gained Into the Treatment of COVID19 by Pulmonary Surfactant and Its Components.Frontiers in immunology · 2022Review
- Response: Commentary: Pattern Recognition Proteins: First Line of Defense Against Coronaviruses.Frontiers in immunology · 2022Article
- Commentary: Pattern Recognition Proteins: First Line of Defense Against Coronaviruses.Frontiers in immunology · 2022Article
- Malondialdehyde Acetaldehyde-Adduction Changes Surfactant Protein D Structure and Function.Frontiers in immunology · 2022Article
- MBL deficiency-causing B allele (rs1800450) as a risk factor for severe COVID-19.Immunobiology · 2021Article
- Ultra- and micro-structural changes of respiratory tracts in SARS-CoV-2 infected Syrian hamsters.Veterinary research · 2021Article
- Serum surfactant protein D in COVID-19 is elevated and correlated with disease severity.BMC infectious diseases · 2021Observational
- Inherited and acquired corona of coronavirus in the host: Inspiration from the biomolecular corona of nanoparticles.Nano today · 2021Article
- Full-Length Recombinant hSP-D Binds and Inhibits SARS-CoV-2.Biomolecules · 2021Article
- A Recombinant Fragment of Human Surfactant Protein D Binds Spike Protein and Inhibits Infectivity and Replication of SARS-CoV-2 in Clinical Samples.American journal of respiratory cell and molecular biology · 2021Article
- Pneumothorax in otherwise healthy non-intubated patients suffering from COVID-19 pneumonia: a systematic review.Journal of thoracic disease · 2021Review
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The severe acute respiratory syndrome coronavirus (SARS-CoV) infects host cells with its surface glycosylated spike-protein (S-protein). Here we expressed the SARS-CoV S-protein to investigate its interactions with innate immune mechanisms in the lung. The purified S-protein was detected as a 210 kDa glycosylated protein. It was not secreted in the presence of tunicamycin and was detected as a 130 kDa protein in the cell lysate. The purified S-protein bound to Vero but not 293T cells and was itself recognized by lung surfactant protein D (SP-D), a collectin found in the lung alveoli. The binding required Ca(2+) and was inhibited by maltose. The serum collectin, mannan-binding lectin (MBL), exhibited no detectable binding to the purified S-protein. S-protein binds and activates macrophages but not dendritic cells (DCs). It suggests that SARS-CoV interacts with innate immune mechanisms in the lung through its S-protein and regulates pulmonary inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.